SR3 Stock Overview Designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. More details
Rewards Risk Analysis No risks detected for SR3 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
STAAR Surgical Company Competitors Price History & Performance
Summary of share price highs, lows and changes for STAAR Surgical Historical stock prices Current Share Price US$23.67 52 Week High US$47.99 52 Week Low US$22.65 Beta 0.60 1 Month Change -9.93% 3 Month Change -23.07% 1 Year Change -11.05% 3 Year Change -67.48% 5 Year Change -25.57% Change since IPO 552.43%
Recent News & Updates
STAAR Surgical Company Maintains Earnings Guidance for the Year 2024 Nov 02
Third quarter 2024 earnings released: EPS: US$0.20 (vs US$0.099 in 3Q 2023) Nov 01
STAAR Surgical Company to Report Q3, 2024 Results on Oct 30, 2024 Oct 23
Second quarter 2024 earnings released: EPS: US$0.15 (vs US$0.13 in 2Q 2023) Aug 08
STAAR Surgical Company Revises Earnings Guidance for the Fiscal Year 2024 Aug 08
STAAR Surgical Company to Report Q2, 2024 Results on Aug 07, 2024 Jul 31 See more updates
STAAR Surgical Company Maintains Earnings Guidance for the Year 2024 Nov 02
Third quarter 2024 earnings released: EPS: US$0.20 (vs US$0.099 in 3Q 2023) Nov 01
STAAR Surgical Company to Report Q3, 2024 Results on Oct 30, 2024 Oct 23
Second quarter 2024 earnings released: EPS: US$0.15 (vs US$0.13 in 2Q 2023) Aug 08
STAAR Surgical Company Revises Earnings Guidance for the Fiscal Year 2024 Aug 08
STAAR Surgical Company to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024 May 09
First quarter 2024 earnings released: US$0.068 loss per share (vs US$0.056 profit in 1Q 2023) May 08
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel May 01
STAAR Surgical Company, Annual General Meeting, Jun 20, 2024 Apr 26
STAAR Surgical Company to Report Q1, 2024 Results on May 08, 2024 Apr 05
Now 30% overvalued after recent price rise Apr 05
STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024 Apr 04
STAAR Surgical Unveils New EVO ICL Data and Latest Innovation for 2024 Apr 02
STAAR Surgical Company Announces Board Changes Mar 12
STAAR Surgical Company Provides Earnings Guidance for the Fiscal Year 2024 Feb 29
Full year 2023 earnings released: EPS: US$0.44 (vs US$0.81 in FY 2022) Feb 27
STAAR Surgical Company to Report Q4, 2023 Results on Feb 26, 2024 Feb 20
Investor sentiment improves as stock rises 16% Jan 15
Broadwood Partners Engages in Discussions with STAAR Surgical Jan 11
Staar Surgical Company Provides Sales Guidance for the Fiscal 2024 Jan 08 STAAR Surgical Company Announces Board Changes Dec 05
Now 23% undervalued after recent price drop Nov 08
Third quarter 2023 earnings released: EPS: US$0.099 (vs US$0.21 in 3Q 2022) Nov 02
STAAR Surgical Company to Report Q3, 2023 Results on Nov 01, 2023 Oct 19
New minor risk - Profit margin trend Aug 03
Second quarter 2023 earnings released: EPS: US$0.13 (vs US$0.27 in 2Q 2022) Aug 03
First quarter 2023 earnings released: EPS: US$0.056 (vs US$0.20 in 1Q 2022) May 05
Staar Surgical Company Announces Sales Guidance for 2023 May 05
Now 20% undervalued after recent price drop Feb 25
Full year 2022 earnings released: EPS: US$0.81 (vs US$0.52 in FY 2021) Feb 23 STAAR Surgical Company to Report Q4, 2022 Results on Feb 22, 2023
Investor sentiment improved over the past week Jan 06
Investor sentiment deteriorated over the past week Dec 21 STAAR Surgical Company Provides Sales Guidance for the Fourth Quarter of 2022
Now 22% undervalued after recent price drop Dec 16
Now 24% undervalued after recent price drop Nov 19
High number of new directors Nov 16
Now 21% undervalued after recent price drop Nov 11
Investor sentiment deteriorated over the past week Nov 09
Third quarter 2022 earnings released: EPS: US$0.21 (vs US$0.13 in 3Q 2021) Nov 03
STAAR Surgical Company Provides Sales Guidance for the Year 2022 Nov 03
Now 22% undervalued after recent price drop Oct 22
STAAR Surgical Company to Report Q3, 2022 Results on Nov 02, 2022 Oct 20
Chief Technology Officer recently sold €522k worth of stock Aug 19
Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.18 in 2Q 2021) Aug 12
High number of new directors Aug 01
STAAR Surgical Company Announces Executive Changes Jul 23
STAAR Surgical Company to Report Q2, 2022 Results on Aug 10, 2022 Jul 21
High number of new directors Jul 02
Now 20% undervalued after recent price drop Jun 18
STAAR Surgical Company Approves Board and Committee Appointment Jun 18
Now 22% undervalued after recent price drop May 07
First quarter 2022 earnings released: EPS: US$0.20 (vs US$0.11 in 1Q 2021) May 06
STAAR Surgical Company, Annual General Meeting, Jun 16, 2022 May 02
STAAR Surgical Company to Report Q1, 2022 Results on May 04, 2022 Apr 21
STAAR Surgical Announces U.S. FDA Approval of EVO Visian® Implantable Collamer® Lenses Mar 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
STAAR Surgical Company Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2021 and Full Year of 2022 Jan 12
Chief Technology Officer recently sold €477k worth of stock Dec 19
Third quarter 2021 earnings released: EPS US$0.13 (vs US$0.085 in 3Q 2020) Nov 05
Insider recently sold €2.6m worth of stock Sep 04
Second quarter 2021 earnings released: EPS US$0.18 (vs US$0.026 loss in 2Q 2020) Aug 05
Broadwood Capital Engages in Discussions with STAAR Surgical Jun 17
Key Executive recently sold €507k worth of stock May 13
First quarter 2021 earnings released: EPS US$0.11 (vs US$0.003 loss in 1Q 2020) May 06
STAAR Surgical Company Provides Earnings Guidance for the Full Year 2021 May 06
Key Executive recently sold €613k worth of stock Mar 07
Full year 2020 earnings released: EPS US$0.13 (vs US$0.32 in FY 2019) Feb 26
Revenue beats expectations Feb 26
STAAR Surgical Company to Report Q4, 2020 Results on Feb 24, 2021 Feb 11
New 90-day high: €88.50 Jan 30
STAAR Surgical Company Announces Board Appointments Jan 28
New 90-day high: €74.50 Jan 14
Insider recently sold €1.4m worth of stock Nov 25
New 90-day high: €70.00 Nov 09
Revenue beats expectations Nov 06
Third quarter 2020 earnings released: EPS US$0.085 Nov 06
STAAR Surgical Company Begins Commercialization of Evo Viva™ Presbyopia Correcting Lens Nov 06
New 90-day high: €57.50 Oct 21
The Klein Law Firm Announces Lead Plaintiff Deadline for the Class Action Filed against Staar Surgical Company Limited Oct 03
Rosen Reminds STAAR Surgical Company Investors of Important Deadline in Securities Class Action – STAA Sep 24
Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in STAAR Surgical Company of Class Action Lawsuit and Upcoming Deadline Sep 17
Independent Director recently sold €6.0m worth of stock Sep 13
First half earnings released Aug 06
STAAR Surgical Company to Report Q2, 2020 Results on Aug 05, 2020 Jul 23 Shareholder Returns SR3 DE Medical Equipment DE Market 7D -0.5% -1.5% 0.7% 1Y -11.0% -7.0% 8.4%
See full shareholder returns
Return vs Market: SR3 underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is SR3's price volatile compared to industry and market? SR3 volatility SR3 Average Weekly Movement 6.6% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SR3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: SR3's weekly volatility (7%) has been stable over the past year.
About the Company STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
Show more STAAR Surgical Company Fundamentals Summary How do STAAR Surgical's earnings and revenue compare to its market cap? SR3 fundamental statistics Market cap €1.17b Earnings (TTM ) €21.23m Revenue (TTM ) €332.69m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SR3 income statement (TTM ) Revenue US$341.22m Cost of Revenue US$72.57m Gross Profit US$268.66m Other Expenses US$246.88m Earnings US$21.78m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 05:01 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/27 Annual Earnings 2023/12/29
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources STAAR Surgical Company is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joanne Wuensch BMO Capital Markets U.S. (Historical) Michael Gorman BTIG John Young Canaccord Genuity
Show 21 more analysts 
